The Wegovy multi-use pen: what the clinical evidence tells you before you inject

What the STEP 1 trial data actually means for people using this pen

The evidence base for Wegovy's multi-use pen is anchored in the STEP clinical programme, the largest of which (STEP 1) enrolled around 1,961 adults with obesity or overweight alongside a weight-related condition. Over 68 weeks, participants using semaglutide 2.4 mg weekly alongside a reduced-calorie diet and increased activity lost around 15% of body weight on average, compared with around 2.4% on placebo. That figure comes from the published trial paper in the New England Journal of Medicine (STEP 1) and is the most cited benchmark for this medicine. Worth knowing: that 15% is an average across the entire population studied; individual outcomes varied, and no trial result is a personal forecast. The pen itself is the delivery mechanism for those doses, it does not change the pharmacology, but using it correctly, as our step-by-step guide explains, does affect how reliably the medicine reaches subcutaneous tissue. Technique matters. The NHS patient information for semaglutide explains what the medicine does and what to expect side-effect-wise, and it is a sensible first read before you lift the cap for the first time.

What the multi-use pen actually involves, the mechanics of a weekly injection

The Wegovy pen is pre-filled, pre-set and disposable once all four doses are used. There is no cartridge to load and no dose to select, the strength is fixed at manufacture for whichever titration level the pen is labelled. Before each injection, you attach a new needle, choose a site (abdomen, thigh or upper arm are all suitable, and rotating between them reduces localised skin reactions), clean the area, and press the pen firmly until you hear or feel it activate. Hold it in place for several seconds, then release. The whole process rarely takes more than a minute once you have done it a few times. Our guide to using your Wegovy pens covers each stage in detail if you want to work through it before your first dose arrives. Used needles are single-use only (one needle, one injection) and should go straight into a sharps container; a 1-litre sharps container is available if you need one. Alcohol swabs are recommended to clean the injection site beforehand. Storage is refrigerated at 2–8°C; consult the Patient Information Leaflet inside the box for the exact window during which a pen can be kept at room temperature, because that window differs from the numbers sometimes quoted online.

The titration schedule and what each pen in the sequence is for

One of the most common misconceptions our prescribers hear is that people expect the first pen to be therapeutic. It is not, and that is deliberate. The starting dose of 0.25 mg exists to let the body adjust (particularly the gut) before the next step up. The schedule moves from 0.25 mg through 0.5 mg, then 1.0 mg, 1.7 mg and finally 2.4 mg, with roughly four weeks at each level. Your prescriber sets the pace; if side effects are significant at one rung, the move up may be delayed. This is why a full overview of Wegovy is worth reading alongside the physical pen instructions, the clinical rationale behind the titration helps people stick with it through the earlier stages when nausea is most noticeable. The multi-use pen format supports this schedule: receiving a pen per dose level keeps quantities aligned with the clinical plan rather than issuing a month's worth of the wrong strength. If you are considering the cost side of treatment, the Wegovy cost guide explains how private pricing works across the titration journey. The MHRA-approved 7.2 mg pen, introduced in April 2026, follows the same multi-use design principle but is intended only for adults who have titrated appropriately under clinical supervision; specific availability is confirmed at consultation.

Side effects, the pancreatitis warning, and when to call for help

Gastrointestinal effects are the most commonly reported. Nausea tends to peak in the days after a new pen or a dose increase, then typically settles within a week or two for most people; constipation, loose stools, indigestion and burping are also common. These are listed in the NHS semaglutide page with guidance on what to monitor. In January 2026, the MHRA issued a Drug Safety Update across GLP-1 medicines drawing attention to acute pancreatitis as an infrequent but potentially serious risk. The signal to act quickly is severe stomach pain that does not ease off and may travel to the back, with or without vomiting. That warrants urgent medical attention rather than waiting to see whether it settles. Injection-site reactions (redness, mild bruising, a small lump) are usually minor and resolve if you keep rotating sites. For anyone who is pregnant, trying to conceive, or breastfeeding, Wegovy is not recommended; the same applies to people under 18. The full contraindication list sits in the Patient Information Leaflet that comes with every pen. Our frequently asked questions cover a range of practical concerns, and the clinical team is reachable through our support line seven days a week if something comes up between injections. If Wegovy is the right fit, checking your eligibility with our prescribers costs nothing and takes a few minutes.